Provided is a means capable of determining the development of myocarditis or the risk thereof by a simple and minimally invasive method. A method of determining the development of myocarditis or risk thereof, wherein it is determined that myocarditis is developed or there is a risk thereof when a concentration or expression amount of ADAM28 in a body fluid sample collected from a subject is reduced compared with a reference value.

The invention provides human AdipoR2 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of AdipoR2 as well as pharmaceutical compositions comprising such compounds.

The present invention includes methods to determine a risk of a cardiovascular disease (CVD) or a subclinical CVD (sCVD) in a subject, by detecting a subset of intermediate monocyte cell populations in the immune cells, wherein a percentage of the subsets as compared to a total intermediate monocyte cell population present in the isolated immune cells is determined; comparing a proportion of the subsets subset of intermediate monocyte cell populations determined with a statistical sample representative of a proportion of equivalent subsets in a total intermediate monocyte cell populations from a subject that does not have a cardiovascular disease; and determining that the subject has an increased risk for cardiovascular disease where the subject has a decrease in the certain subsets, has an increase in another subset, or both, as compared to the statistical sample.

This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.

Provided are a composition for diagnosing vascular disease including an agent measuring a level of interleukin 12 receptor β2 protein in the blood, and a kit for diagnosing vascular disease including the same. Further, provided is a method for diagnosing vascular disease, the method including the step of measuring a level of interleukin 12 receptor β2 protein in a blood sample separated from an individual suspected of having vascular disease. Furthermore, provided are a composition for preventing or treating vascular disease including an interleukin 12 receptor β2 activity inhibitor, and a method of screening a therapeutic agent for vascular disease, the method including the step of treating smooth muscle cells with a test agent for vascular disease treatment and measuring an expression level of interleukin 12 receptor β2.

A method of diagnosing and treating a cardiovascular disease in a patient, the method comprising the steps of: determining whether the patient has an increase in stem cell memory T (T.sub.scm) cells by: obtaining or having obtained a biological sample from the patient; performing or having performed an assay on the biological sample to determine the amount of T.sub.scm in the patient, wherein the T scm are at least one of: CD8+CD45RA+CCR7+CD27+CD28+CD95+ T cells, CD4+CD45RA+CCR7+CD27+CD28+CD95+ T cells, or CD8+CD3+CD45RA+CCR7+C D45RO− CD95+ T cells; identifying that the patient has an increase in T.sub.scm when compared to the amount of T.sub.scm in a healthy patient; and if the patient has an increase in T.sub.scm, then administering therapy for the treatment of the cardiovascular disease to the patient.

The invention “use of biomarker or biomarkers combination in preparing a diagnostic reagent for fulminant myocarditis and a drug for fulminant myocarditis” belongs to the field of disease diagnostic reagents and drugs. The biomarker comprises Siglec-5. The biomarkers combination is further selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-Cadherin, CD14, CTLA4. The invention finds that the levels of the biomarker in plasma of patients with fulminant myocarditis is increased, and proves that the biomarker plays a role in diagnosing fulminant myocarditis and a role as a drug target in relieving and/or improving fulminant myocarditis. The level of the biomarker can be detected to forecast or auxiliary diagnose fulminant myocarditis or estimate prognosis of fulminant myocarditis. Meanwhile, level of the biomarkers is controlled through drugs, more intensified diagnosis and follow-up treatment can be carried out on diseases, and the biomarkers have huge clinical application value.

The present invention provides methods of treating prediabetes, hyperglycemia, type 2 diabetes, AMIS syndrome, and obesity in a subject by administering to the patient HISS. The present invention also provides methods of diagnosing AMIS syndrome in a patient. Additionally, the present invention provides a method of shifting nutrient storage in meat-producing livestock to muscle rather than fat.

Antibodies and antigen-binding fragments of antibodies that bind to human fractional C-Reactive Protein (fracCRP), kits containing these antibodies and antibody fragments, and assays using these antibodies and antibody fragments.

The invention relates to a method for predicting or diagnosing a risk of bioprosthetic valve degeneration. Further, the invention relates to a medical device, in particular a bioprosthetic valve coated with EPCR less prone to degeneration and/or calcification once implanted.